Clinical Trials

6 enrolled

Melanoma

NCT02027935 2024-10-08

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

16 enrolled 8 charts

Melanoma

NCT02107755 2024-05-21

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

8 enrolled 12 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02519322 2024-04-05

Neoadjuvant and Adjuvant Checkpoint Blockade

53 enrolled 10 charts

DermatologicGastrointestinalSarcoma

Uveal Melanoma, Melanoma

NCT01738139 2024-03-21

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Phase 1 Completed

68 enrolled

Melanoma, Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

DermatologicGastrointestinalLymphoidOther hematologic neoplasm

3 enrolled 5 charts

Burkitt Lymphoma, Colonic Neoplasms, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mycosis Fungoides, Rectal Neoplasms, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Phase 1/2 Completed

140 enrolled 23 charts

CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT02203604 2023-07-18

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Terminated

9 enrolled 13 charts

Melanoma

NCT03396952 2022-10-13

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

27 enrolled 13 charts

Melanoma

NCT01940809 2022-03-10

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

15 enrolled

Melanoma

NCT03425461 2021-04-02

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

6 enrolled

Melanoma

NCT01970527 2020-02-13

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Phase 2 Terminated

23 enrolled 13 charts

Melanoma

NCT02158520 2020-01-21

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

24 enrolled 10 charts

DermatologicGastrointestinalGynecologic

Uveal Melanoma, Melanoma

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

NCT00039091 2018-09-05

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

DermatologicGynecologicMyeloidOther hematologic neoplasmThoracic

26 enrolled

Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Melanoma, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Phase 1/2 Withdrawn

BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01740401 2017-12-06

CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma

Phase 2 Terminated

10 enrolled 6 charts

Melanoma

NCT00871481 2017-04-19

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase 1/2 Completed

10 enrolled

Melanoma

NCT00050102 2011-01-28

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma